Top 5 Biotech Startup Investors in Isle of Man in April 2025

Last updated: Apr 2025 A list of 5 angel investors and VC (Venture Capital) funds that invest in Biotech startups based in Isle of man. We rank investors based on the number of investments they made in Biotech companies from Isle of man. We update this investor list every month.

Top 5 Biotech Startup Investors in Isle of Man in April 2025

Investor	Biotech Isle of Man investments
Greg Bailey	1
Juvenescence	1
Foresite Capital	1
Andrew Banks	1
Jim Mellon	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.

Investment focus

Biotechnology, Pharmaceutical, Medical
Seed, Series A, Funding Round
United States, Isle of Man

Portfolio highlights

Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
Biohaven Pharmaceutical — Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipelineproducts include BHV3000-301, BHV3000-302, BHV3000-303, and others.

We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.

Investment focus

Biotechnology, Pharmaceutical, Health Care
Funding Round, Series A, Debt Financing
United States, Hong Kong, Isle of Man

Portfolio highlights

LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.
Souvien Therapeutics — Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, United Kingdom, Australia

Portfolio highlights

Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
Pleno — Pleno Inc. is a multi-omic instrument platform company democratizing biological target detection for clinical testing and biomedical research. The company’s proprietary Hypercoding™ technology leverages signal processing techniques from the telecommunications industry to deliver targeted biological information at unprecedented scale, precision, andperformance.
Ikena Oncology — Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signalingpathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.

Andrew Banks - Chairman and Co-Founder @ ABRY Partners

Investment focus

Biopharma, Biotechnology, Pharmaceutical
Seed
Isle of Man

Portfolio highlights

Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.